Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

NCT06409702 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

59

Enrollment

OTHER

Sponsor class

Conditions

Newly Diagnosed
High Risk
MRD
Multiple Myeloma

Interventions

DRUG: Carfilzomib
DRUG: Daratumumab
DRUG: Lenalidomide
DRUG: Dexamethasone
DRUG: VRD for first-cycle induction therapy

Sponsor

The First Affiliated Hospital of Soochow University